Geron (GERN) soars 15.1% after saying that its imetelstat treatment performed well in Phase II...

|About: Geron Corporation (GERN)|By:, SA News Editor

Geron (GERN) soars 15.1% after saying that its imetelstat treatment performed well in Phase II trials of patients with a chronic blood disorder called essential thrombocythemia. Geron designed the trial to provide a proof of concept for the potential use of imetelstat to treat blood cancers. Geron shares were slammed last week after it said it was stopping the development of therapies for brain cancer. (Presentation)